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Summary The data from two prospective randomised phase III trials that were initiated by the West
Midlands Ovarian Cancer Study Group (WMOCSG) in 1981 and 1986, recruiting 167 and 195 patients
respectively, have been pooled and the survival patterns of the 362 patients treated for advanced epithelial
ovarian cancer within clinical trials in the West Midlands over the 10 year period (1981-91) have been
explored. All patients had histologically proven epithelial ovarian cancer and all had residual disease after
primary surgery, with the majority having stage III/IV disease. The primary treatment for all patients was
debulking surgery followed by platinum-based chemotherapy. Eligible patients were further randomised to
undergo a second debulking operation. The main end point, survival, was assessed using Kaplan-Meier curves
and the log-rank test. A Cox proportional hazards model identified performance status (P=0.002), residual
disease (P=0.005) and albumin level (P=0.04) as independent prognostic factors. A multivariate model to
predict survival curves for patients with the best and worst prognoses was developed with predicted 5 year
survival of 30% and 3% for those in the best and worst prognostic groups respectively. The identification of
clinical interventions to improve outcome is an urgent matter since the prognosis for patients with advanced
ovarian cancer remains poor.
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Ovarian cancer has an annual incidence in the UK of just
over 5000 women, and the disease still has a poor long-term
outlook for the majority of women. The definition of
significant, clinically important and clinically available prog-
nostic factors for these patients is important and interesting.
Prognostic factors have been identified over the past 10
years, but these have been based on patients being treated at
specialist oncology centres (Van Houwelingen et al., 1989;
Marsoni et al., 1990) or relate to the preplatin era (Swener-
ton et al., 1985). The West Midlands Ovarian Cancer Study
Group (WMOCSG), in collaboration with the CRC Trials
Unit in Birmingham, have run a succession of phase III
clinical trials in ovarian cancer since 1981. A data set to
study prognostic factors for patients with gross residual
disease remaining after primary surgery for epithelial ovarian
cancer was obtained by pooling the patients entered into the
first and second West Midlands trials. Patients in whom total
macroscopic clearance of disease was achieved at primary
surgery were entered into a separate study so this data set
comprises all patients fitting the above criteria treated within
WMOCSG phase III clinical trials over the 10 year period
1981-91. The first trial evaluated the role of second-look
laparotomy (SLL), whole abdominal radiotherapy (Dembo et
al., 1979) and chlorambucil following platinum-based chemo-
therapy (Luesley et al., 1988), while the second trial
evaluated the role of intervention debulking surgery (IDS)
(Redman et al., 1994) and intensification of chemotherapy.
Recruitment into these trials has been good and represents
approximately 20% of women with ovarian cancer in the
West Midlands; the maximum potential number of eligible
patients being estimated from the number of cases occurring
within the region over the period, discounting those with
non-epithelial tumours, early stage disease or who would not
have been fit enough to tolerate platinum-based chemo-
therapy. This is a 4-fold higher recruitment into clinical trials
than the national average, which is estimated to be approx-
imately 5% or less.
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The long-term follow-up, survival patterns and prognostic
factors for this group of 362 patients treated for epithelial
ovarian cancer in the West Midlands over the 10 year period
1981-91 are presented. These results suggest that the
development of an index to identify good and poor prognos-
tic groups may be possible and could help in targeting
optimal therapy for patients with this disease.
Patients and methods
In the first study 167 patients were given five courses of
cisplatin at 100 mgm-2 following primary laparotomy. They
were then randomised, stratifying by residual disease after
primary surgery (<2 cm or >2 cm), to one of three con-
solidation treatment arms: (1) second-look laparotomy (SLL)
plus radiotherapy; (2) SLL plus 12 courses of chlorambucil;
or (3) 12 courses of chlorambucil only. The second-look
laparotomy was carried out, where applicable, within 6 weeks
of the last course of chemotherapy. The second study inves-
tigated intervention debulking surgery (IDS) in patients who
had significant amounts of residual disease following primary
surgery and subsequently responded to chemotherapy.
Patients who were unlikely to benefit from second surgery
(i.e. those in whom a total abdominal hysterectomy, bilateral
salpingo-oophorectomy and ometectomy had been performed
at primary surgery and <2 cm of residual disease remained
or those with Stage IV disease) were randomised between the
standard chemotherapy (CP) consisting of eight courses of
cisplatin 75 mgm2 and cyclophosphamide 750 mgm2 and
an alternative non-cross-resistant chemotherapy consisting of
three cycles of cisplatin 75 mg m-2, doxorubicin 50 mgm-2
and bleomycin 15 mg m-2 followed by five courses of cyclo-
phosphamide starting at 1 gm-2, increasing by 0.5 g m-2
each course to a maximum of 3 gm-2 (PAB Esc-Cyclo).
Patients who were suitable for IDS were randomised in a
2 x 2 factorial design to IDS or no IDS plus either CP or
PAB Esc C. As in the first study, the randomisation was
stratified by residual disease (<2cm, > 2cm). In 1989, an
interim analysis was carried out and showed no significant
difference between the two regimens of chemotherapy in
terms of survival. The frequency and severity of toxicity was,Advanced ovarian cancer in randomised clinical trials
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however, significantly greater in the PAB Esc C arm of the
trial and hence randomisation to PAB Esc C was discon-
tinued in July 1989. All patients who entered the study after
that date received cisplatin and cyclophosphamide. The
results from both trials were reported in 1988 and 1994
respectively (Luesley et al., 1988; Redman et al., 1994).
Data were collected prospectively from all patients and
stored in the ORACLE database on a VAX 11/730 minicom-
puter at the Cancer Research Campaign Trials Unit. All data
manipulation and analyses were carried out on an intention-
to-treat basis using SAS statistical software (SAS Institute,
SAS Circle, Cary, NC, USA). Survival curves were calculated
by the product-limit method (Kalbfleisch and Prentice, 1980)
and the log-rank test (Kalbfleisch and Prentice, 1980) was
used to test for differences between the curves. Survival has
been calculated from the date of randomisation to death for
patients who have died and from the date of randomisation
to the censor date, 1 January 1993, for those who are still
alive.
The Cox proportional hazards method (Cox, 1972) was
used to build a multivariate model to identify independent
prognostic factors for survival and assess relative risks. The
Table I Summary of treatments given
First trial Second trial
(1981-85) (1986-91)
Cisplatin + Chlorambucil 56
Cisplatin + second-look 54
laparotomy + chlorambucil
Cisplatin + second-look 57 -
laparotomy + radiotherapy
Cisplatin + cyclophosphamide - 85
Cisplatin + cyclophosphamide + - 25
intervention debulking surgery
Cisplatin + doxorubicin +bleomycin - 66
+ escalating cyclophosphamide
Cisplatin + doxorubicin +bleomycin - 19
+ escalating cyclophosphamide +
intervention debulking surgery
Total 167 195
model was built using forward selection of variables where
the criteria for inclusion was P<0.05. The proportionality
assumption of the model was tested graphically and the
hazard ratios with their confidence intervals calculated from
the regression coefficients and standard errors of the final
model. Predicted survival curves for patients with the best
and worse prognoses were then calculated.
Results
Details of the number of patients randomised to each treat-
ment are given in Table I. A total of 362 patients (99%) were
followed up for at least 2 years, with median follow-up of 6.5
years. Survival is poor, with only 35% surviving 2 years
(95% CI; 30, 40%) and 14% surviving 5 years (95% CI; 10,
18%), (Figure 1).
Patient characteristics for each trial and the group as a
whole are shown in Table II. The distribution of age and
FIGO stage in the second trial were similar to that seen in
the first trial. However, women entering the two trials were
not balanced as regards histological type, grade, residual
disease after primary surgery and performance status.
Log-rank analysis gave similar results when each trial was
analysed separately. In the first trial performance status was
the only significant prognostic factor (P=0.0001) whereas in
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Figure 1 Overall survival for all patients.
Table II Patient characteristics for each trial
First trial Second trial
(1981-85) (1986-91)
n= 167 n= 195 Total
No. (%) No. (%) n = 362 x2 p
FIGO stage
II 12 (7) 19 (11) 31 1.51 0.47
III 124 (75) 122 (70) 246
IV 30 (18) 32 (18) 62
Unknown 1 22 23
Histological type
Serous 72 (49) 56 (64) 128 18.08 0.003**
Endometrioid 16 (11) 17 (20) 33
Mucinous 15 (10) 2 (2) 17
Clear cell 13 (9) 4 (5) 17
Undifferentiated 27 (19) 5 (6) 32
Other 3 (2) 3 (3) 6
Unknown 21 108 129
Histological grade
Poor 70 (49) 32 (37) 102 8.99 0.01*
Moderate 37 (26) 39 (45) 76
Well 35 (25) 15 (18) 50
Unknown 25 109 134
Residual disease
<2 cm 47 (28) 72 (41( 119 6.57 0.01*
>2cm 120 (72) 102 (59) 222
Unknown - 21 21
Performance status
WHO grade 0 42 (42) 28 (18) 70 21.77 <0.0001**
WHO grade 1 47 (47) 79 (52) 126
WHO grade> 11 (11) 45 (30) 56
Unknown 67 43 110
Median age (range) 58 (22,70) 58 (33,78) 58
*Significant. **Highly significant.
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the second trial residual disease (P=0.0001) and stage
(P=0.0003) were highly significant in addition to perfor-
mance status (P=0.01). Creatinine clearance, albumin level
and time from primary surgery until start of chemotherapy
are of weaker prognostic importance (P<0.09).
The data were then pooled and the analysis repeated as
shown in Table III. Performance status (P=0.0001), residual
disease (P=0.0001) and stage (P=0.0002) are highly
significant. However, creatinine clearance, albumin level, time
from primary surgery to start ofchemotherapy and histology
are also significant (P<0.05), confirming the trends seen in
the previous analysis.
This data set was also analysed adjusting for trial effects.
There is no significant differences between the trials (P=0.64)
(Figure 2) and the results for prognostic factors were iden-
tical when the analysis was stratified by trial and by residual
disease. Treatments were combined in several different ways
to form the large subgroups detailed in Table IV. There were
no significant treatment effects.
A Cox regression analysis was initially carried out on the
138 patients for whom we had a complete set of prognostic
data. The variables considered were trial, treatment, perfor-
mance status, residual disease, stage, histological grade and
type, albumin level, creatinine clearance, time from primary
surgery to start ofchemotherapy, age and menopausal status.
The first factor to be selected was performance status (WHO
grade < 1, > 1), followed by residual disease (<2 cm,
>2 cm) and finally histology (clear cell, or not clear cell). No
other variables enter the model. Although patients with clear
cell carcinoma appear to have a much poorer prognosis than
those with the other histological types, histology was drop-
ped from the final model because there were only 17 cases
with clear cell in the entire data set.
The analysis was run excluding histological type from the
set of prognostic variables and this increased the data set to
213 patients. Again performance status was the first variable
to be selected, followed by residual disease and albumin level.
These three factors were shown to be independent by exc-
luding each in turn (in addition to histological type) from the
set of possible prognostic variables and allowing those
remaining to compete to enter the model in its place when
the analysis was re-run. In each of the three cases no new
variables entered the model and the order in which variables
entered was preserved, i.e. when performance status was
excluded residual disease entered the model first followed by
albumin level; when residual disease was excluded perfor-
mance status entered the model first followed by albumin
level; and when albumin level was excluded performance
status entered the model first followed by residual disease.
The regression coefficients, risk ratios and their confidence
intervals are shown in Table V. This multivariate analysis
confirms the results of the univariate analysis and demon-
strates that performance status, residual disease and albumin
level are independent prognostic factors.
Predicted survival curves were obtained from this model
for patients with the best and worst prognoses (Figure 3).
These curves illustrate the significantly different survival dist-
ributions for these patients with median survival of 27
months for the good prognosis group and 10 months for the
poor prognosis group. The 5 year survival for the good and
poor prognosis groups was 30% and 3% respectively.
Discussion
Although neither of these trials reported any statistically
significant differences between treatments, clinically
significant differences may exist but remain undetected
because both trials were small, recruiting 167 and 195
patients respectively. Using a 2 year survival rate of 35% on
the standard treatment and a significance level of 5%, the
first trial had an 80% chance of detecting a real difference in
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Figure 2 Survival distribution by trial (chi-squared = 0.21,
P=0.64). (----), First trial; ( ), second trial.
Table III Univariate analysis of the pooled data
Hazard ratio
Log-rank (95% confidence
Factor Grouping Number x2 p interval
Age < 58 184 3.23 0.07
>58 178
Creatinine clearance < 60 73 6.35 0.01* 1
>60 226 0.7 (0.49, 1.54)
Albumin < 35 150 6.5 0.01* 1
>35 140 0.73 (0.57, 0.93)
Performance status WHO grade 0 70 19.06 0.0001** 1
WHO grade 1 126 1.37 (0.89, 2.11)
WHO grade> 1 56 2.31 (1.42, 3.76)
Residual disease < 2 119 17.95 0.0001** 1
>2 222 1.68 (1.31, 2.16)
FIGO stage II 31 17.09 0.0002** 1
III 246 1.61 (0.78, 3.32)
IV 62 1.99 (0.89, 4.46)
Menopausal status Pre 97 1.99 0.16
Post 265
Time from primary (21 days 190 5.85 0.02* 1
surgery to start of >21 days 143 1.33 (1.05, 1.68)
chemotherapy
Histology Serous 128 9.18 0.03* 1
Endometrioid 33 0.86 (0.57, 1.49)
Mucinous 17 0.88 (0.58, 1.34)
Clear cell 17 2.11 (1.26, 3.56)
Differentiation Well 50 1.50 0.47
Moderate 76
Poor 102
*Significant. **Highly significant.Advanced ovarian cancer in randomised clinical trials
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Table IV Treatment
Log-rank
Factor Grouping Number x2 p
Trial First study 167 0.21 0.64
Second study 195
Chemotherapy P 167 1.22 0.54
PAB Esc C 85
CP 110
Treatment P + SLL + CHLOR 54 3.17 0.79
P + SLL + XRT 57
P + CHLOR 56
CP + IDS 25
CP 85
PAB + IDS 19
PAB 66
Second surgery SLL or IDS 155 1.83 0.18
No SLL or IDS 104
Table V Summary of the Cox multiple regression analysis (n = 213)
Regression Hazard 95% Confidence
Variable Group coefficient P-value ratio interval
Performance < 1 0.53 0.002 1
status > 1 1.71 (1.21, 2.39)
Residual < 2 cm 0.44 0.005 1
disease >2cm 1.56 (1.13, 2.12)
Albumin < 35 -0.31 0.04 1
level >35 0.73 (0.55, 0.98)
excess of 25%. Similarly, with 85 patients on each
chemotherapy and 45 in each arm of the surgery randomisa-
tion, the second trial had an 80% chance of detecting a 2
year survival difference in excess of 20% between the
chemotherapies and 28% between the IDS and no IDS arms.
These trials were initiated during the early 1980s when imp-
rovements of up to 30% in 2 year survival were widely
thought to be achievable. This has since been shown to be
unrealistic and clinicians designing trials in advanced ovarian
cancer in the 1990s would probably judge that an absolute
improvement of 10% in 2 year survival would be of clinical
importance but it is clear that these trials were unlikely to
detect such a change.
The distribution of performance status also appears to
have changed between the first and second trials but this may
be due to changes in the scale used rather than any real
change in the patient population. Data from the first trial
were translated from the Karnofsky performance scale (Kar-
nofsky and Burchenal, 1949) with ten grades to the WHO
performance scale with only five grades when the data were
pooled. Whilst there has obviously been a loss of accuracy as
a result of this translation, comparison of survival curves by
performance status for the two trials confirmed that such
pooling was reasonable.
The Cox regression model for this data identifies perfor-
mance status, residual disease and albumin level as important
prognostic factors. Ths risk of death for an individual with
performance status > 1 is 70% greater than that for an
individual with performance status <1. The 95% confidence
interval is wide but shows the increased risk to be at least
21%. Similarly, residual disease >2 cm is associated with a
nearly 60% increase in risk of death and lower confidence
level of 13%. Conversely, albumin level >35 is associated
with a 27% reduction in risk but again the confidence inter-
val is wide, suggesting that the reduction in risk could be as
small as 2%. These results are broadly in line with the
findings of similar studies in the Netherlands (Van Houwel-
ingen et al., 1989) and Italy (Marsoni et al., 1990) and
confirm performance status and residual disease as key prog-
nostic factors.
The pooled analysis of the West Midlands trials has shown
alterations in surgical practice, with a greater proportion of
patients having optimal surgery (<2 cm maximum residual
tumour) in the later trial (28% vs 41%). This probably
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Figure 3 Predicted survival curves from the Cox regression
model. ( ), Performance status < 1, residual disease < 2 cm,
albumin level >35; (----), performance status > 1, residual
disease >2cm, albumin level < 35.
reflects greater adherence to the theory of Griffiths et al.
(1979), claiming improved chemotherapeutic efficacy with
residual tumour load of <2 cm, that improved chemo-
therapeutic effect is achieved in those where the tumour load
is reduced to <2 cm. Reports continue to accumulate in the
literature, indicating the effect of platinum rather than
tumour volume reduction as influencing survival patterns
(Nejit et al., 1991; Venesma et al., 1994). Griffiths' theory
was based on the retrospective analysis of 102 patients, with
estimates of tumour volume obtained from the surgical notes
in 75% of cases and on questioning the operating surgeon in
25% (Griffiths, 1975). The accuracy of these estimates re-
mains questionable. Subsequent to this, Griffiths undertook a
prospective study indicating improved survival in those
patients in whom residual tumour load was reduced to
<2 cm. This was based on only 24 patients and in clinical
trials would constitute a phase II study (Griffiths and Fuller,
1978). With such findings the need to progress to a ran-
domised trial is evident - a study which is presently ongoing
in the West Midlands.
Patients entered into clinical trials must fit eligibility
criteria which may result in the overselection of good prog-
N"Advancedovarian cancer in randomised clinical trials
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nostic groups. The national 5 year survival figures for those
with stage II, III and IV disease are 45%, 17% and 5%
(Cancer Research Campaign, 1991) compared with the results
from this analysis of 22%, 14% and 5% respectively. The
apparent difference for patients with stage II disease may be
because only those with a high risk of recurrence were con-
sidered suitable for randomisation.
The model obtained from this analysis shows that this set
of patients, whose overall prognosis is poor, can be further
subdivided into predicted good and bad prognostic groups.
Such a model is, of course, data dependent and may not be
generalisable to patients in similar clinical trials or the
population of patients with advanced ovarian cancer as a
whole. Our results suggest that difference between the
predicted survival curves for good and bad prognostic group
is large (30% vs 3%) at 5 years and that even for the best
prognostic group 5 year survival is poor. In the subset of
data used for the Cox regression model (n=213) 20% of
patients fell within the good prognosis group and 12% within
the bad. It is very important, therefore, that this model is
validated fully on other data sets in order to assess the utility
of these prognostic factors and predicted survival curves in a
clinical setting.
Although data were collected prospectively in these trials
there may be other factors that need to be explored in order
to improve our understanding of this disease. The
identification of clinical interventions which improve out-
come is an urgent matter, recognised as such by the Consen-
sus Statement (Allen et al., 1993), which states that all
patients with ovarian cancer should, if possible, be included
in therapeutic trials to allow for advances in treatment to be
defined as rapidly as possible.
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